Introduction: this is an update of the November 2004 Therapeutics Initiative systematic review report. Research questions: “Are there any clinical advantages to the use of clopidogrel, in combination with ASA, for twelve months as compared to thirty days in medically treated patients following ACS (unstable angina or non-ST elevation myocardial infarction)?” “Are there any incremental risks … [Read more...]
The Drug Assessment Working Group (DAWG) is committed to analyze scientific evidence on the effectiveness and safety of drug therapies used in Canada. They systematically review and, when appropriate, critically appraise research relevant to new and existing drugs. Often the goal is to discover whether a new drug provides a therapeutic advantage over existing similar drug therapy for a clinical condition.
The Therapeutics Initiative has a dedicated team of researchers that is committed to the highest standards of research. In addition to reports on various new and existing drugs, the DAWG also contributes to the federal Common Drug Review (CDR), a national program set up to reduce duplication, and provide equal access to high level evidence and expert advice, thereby contributing to the quality and sustainability of Canadian public drug plans. The DAWG has contributed to many of the CDR reviews.
Below is a list of completed DAWG reports with links to the executive summaries.
Introduction: This report is an updated systematic review of rituximab done by CDR in November 2006 and also attempts to answer the 2 research questions stated below. Drug Rituximab is categorized as anti-neoplastic. It is indicated “in combination with methotrexate (MTX) to reduce signs and symptoms in adult patients with moderately to severely active RA who have had an inadequate response or … [Read more...]
Introduction: This is an update to the February 2005 Therapeutics Initiative review of Imiquimod 5% cream (Aldara™) for the treatment actinic keratosis. Drug Imiquimod is an immune response modifier indicated for the treatment of clinically typical, non-hyperkeratotic, actinic keratosis on the face or balding scalp in adults. It is recommended to be applied once a day, twice weekly for a … [Read more...]
Introduction: This report is a systematic review of Dovobet™ ointment in the treatment of adult patients with psoriasis vulgaris. Drug Dovobet™ (Betamethasone dipropionate/Calcipotriol) is a combination of the vitamin D analogue calcipotriol and the corticosteroid betamethasone dipropionate. Calcipotriol (Cal) is a non-steroidal antipsoriatic agent, derived from naturally occurring vitamin D. It … [Read more...]
Background information of the condition Venous thromboembolism (VTE) in patients with cancer: Cancer is a major risk factor for VTE with the 12-month cumulative incidence of recurrent VTE three times higher than patients without cancer [20.7% vs. 6.8%, respectively] (1). Oral anticoagulants (OAC) - warfarin and acenocoumarol, are the standard long-term (3-6 month) therapy for secondary … [Read more...]
This is the summary of a systematic review assessing the comparative safety and efficacy of Seasonale (ethinyl estradiol 30 μg, levonorgestrel 150 μg, extended 91-day cycle), in the prevention of pregnancy in sexually active women of reproductive age. Drug This oral contraceptive (OC) combines an estrogen, ethinyl estradiol (EE) 30 μg, and a progestin, levonorgestrel (LNG)150 μg, commonly … [Read more...]
This is the summary of an update of the February 2005 Therapeutics Initiative systematic review of imiquimod 5% cream (Aldara) for the treatment of actinic keratosis. Drug Imiquimod is an immune response modifier indicated for the treatment of clinically typical, non-hyperkeratotic, actinic keratosis on the face or balding scalp in adults. It is recommended to be applied once a day, twice … [Read more...]
This is a summary of a systematic review of calcipotriol/betamethasone dipropionate (Dovobet) ointment in the treatment of adult patients with psoriasis vulgaris. Drug Dovobet (calcipotriol/betamethasone dipropionate) is a combination of the vitamin D analogue calcipotriol and the corticosteroid betamethasone dipropionate. Calcipotriol (Cal) is a non-steroidal antipsoriatic agent, derived from … [Read more...]
Background Information of the Condition Bipolar disorder Type I is characterized by at least one manic episode, with or without major depression. Patients are often symptomatically ill for nearly half of the time and their most frequent symptoms are depression, followed distantly by mania/hypomania, and then mixed episodes.1 Drugs used for treatment of acute mania are: lithium, valproate … [Read more...]
Background Information of the Condition Chronic bronchitis is a subset of chronic obstructive pulmonary disease defined by a productive cough for at least 3 months in duration in each of 2 consecutive years, which may include an acute exacerbation of increased sputum production and purulence, and increased dyspnea. An increased respiratory rate and wheezing, lethargy and elevated temperature are … [Read more...]